Compare CVS Health Corp (CVS) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Rivian Automotive, Inc. — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B). The key difference: CVS Health Corp is far larger — about 5.4× Rivian Automotive, Inc.'s market cap, and CVS Health Corp pays a 3.03% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Rivian Automotive, Inc. for 61 Days on average.
| CVS | RIVN | |
|---|---|---|
Market Cap | $112.29B | $20.75B |
Volume | 7,763,676 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $22.45 |
52-Week Low | $70.08 | $12.50 |
Typical Hold Time | 83 Days | 61 Days |
Enterprise Value | $174.64B | $20.79B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% with a bearish technical signal. The company shows strong revenue growth to $402.1B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus is overwhelmingly bullish with 85% buy ratings and a $111.20 price target representing 27% upside. Recent news highlights Aetna's 2027 Medicare plan enhancements and quarterly dividend declarations.
CVS presents a compelling value opportunity with attractive valuation metrics (P/E 23.17, P/S 0.27) and strong analyst support. Key risks include reimbursement pressure, regulatory scrutiny from ongoing investigations, and declining net margins. The stock's current technical weakness contrasts with solid fundamentals and positive earnings momentum.
Rivian (RIVN) trades at $14.33, down 0.07% on the day, with a bearish technical signal from moving averages. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates, but maintained full-year guidance, causing mixed market reactions. Financially, revenue growth continues while losses narrow, with a net income margin of -54.95% in 2025. Analyst consensus is a Buy with a $16.89 price target, though cash burn remains a concern with negative operating cash flow.
Rivian's outlook hinges on scaling R2 production and advancing autonomy, offering growth potential, but high cash burn, competitive pressures, and execution risks pose significant challenges. The stock presents a speculative opportunity for investors betting on EV adoption and operational improvements, balanced by substantial financial and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
